One-year access to more than 500 world journals available in the system
-
http://medilib.ir
- Duration of Time : 365 Day
Price : 300$- Special Price : 100$
Association of Low Plasma Transthyretin Concentration With Risk of Heart Failure in the General Population
Anders M. Greve, MD, PhD1; Mette Christoffersen, MSc, PhD1; Ruth Frikke-Schmidt, MD, DMSc1,2,3; B?rge G. Nordestgaard, MD, DMSc2,3,4; Anne Tybj?rg-Hansen, MD, DMSc1,2,3,4
doi : 10.1001/jamacardio.2020.5969
JAMA Cardiol. 2021;6(3):258-266
Importance Several lines of evidence support low plasma transthyretin concentration as an in vivo biomarker of transthyretin tetramer instability, a prerequisite for the development of both wild-type transthyretin cardiac amyloidosis (ATTRwt) and hereditary transthyretin cardiac amyloidosis (ATTRm). Both ATTRm and ATTRwt cardiac amyloidosis may manifest as heart failure (HF). However, whether low plasma transthyretin concentration confers increased risk of incident HF in the general population is unknown.
Applicability of US Food and Drug Administration Labeling for Dapagliflozin to Patients With Heart Failure With Reduced Ejection Fraction in US Clinical Practice
Muthiah Vaduganathan, MD, MPH1; Stephen J. Greene, MD2; Shuaiqi Zhang, MS2; Maria Grau-Sepulveda, MD2; Adam D. DeVore, MD, MHS2; Javed Butler, MD, MPH, MBA3; Paul A. Heidenreich, MD4; Joanna C. Huang, PharmD5; Michelle M. Kittleson, MD, PhD6; Karen E. Joynt Maddox, MD, MPH7; James J. McDermott, PhD5; Anjali Tiku Owens, MD8; Pamela N. Peterson, MD, MPH, MSPH9; Scott D. Solomon, MD1; Orly Vardeny, PharmD10; Clyde W. Yancy, MD, MSc11,12; Gregg C. Fonarow, MD13,14
doi : 10.1001/jamacardio.2020.5864
JAMA Cardiol. 2021;6(3):267-275
Importance In May 2020, dapagliflozin was approved by the US Food and Drug Administration (FDA) as the first sodium-glucose cotransporter 2 inhibitor for heart failure with reduced ejection fraction (HFrEF), based on the Dapagliflozin and Prevention of Adverse Outcomes in Heart Failure (DAPA-HF) trial. Limited data are available characterizing the generalizability of dapagliflozin to US clinical practice.
Associations of Adiposity, Circulating Protein Biomarkers, and Risk of Major Vascular Diseases
Yuanjie Pang, DPhil1; Christiana Kartsonaki, DPhil2,3; Jun Lv, PhD1; Zammy Fairhurst-Hunter, DPhil2; Iona Y. Millwood, DPhil2,3; Canqing Yu, PhD1; Yu Guo, MSc4; Yiping Chen, DPhil2,3; Zheng Bian, MSc4; Ling Yang, PhD2,3; Junshi Chen, MD5; Robert Clarke, MD2; Robin G. Walters, PhD2,3; Michael V. Holmes, PhD2,3,6; Liming Li, MD1; Zhengming Chen, DPhil2,3
doi : 10.1001/jamacardio.2020.6041
JAMA Cardiol. 2021;6(3):276-286
Importance Obesity is associated with a higher risk of cardiovascular disease (CVD), but little is known about the role that circulating protein biomarkers play in this association.
Clinical Utility of Lipoprotein(a) and LPA Genetic Risk Score in Risk Prediction of Incident Atherosclerotic Cardiovascular Disease
Mark Trinder, MSc1,2; Md Mesbah Uddin, PhD2; Phoebe Finneran, BS2,3,4; Krishna G. Aragam, MD, MS2,3,4,5; Pradeep Natarajan, MD, MMSc2,3,4,5
doi : 10.1001/jamacardio.2020.5398
JAMA Cardiol. 2021;6(3):287-295
Importance Lipoprotein(a) is a highly heritable biomarker independently associated with atherosclerotic cardiovascular disease (ASCVD). It is unclear whether measured lipoprotein(a) or genetic factors associated with lipoprotein(a) can provide comparable or additional prognostic information for primary prevention.
Outcomes for Out-of-Hospital Cardiac Arrest in the United States During the Coronavirus Disease 2019 Pandemic
Paul S. Chan, MD, MSc1,2; Saket Girotra, MD, SM3; Yuanyuan Tang, PhD1; Rabab Al-Araji, MPH4; Brahmajee K. Nallamothu, MD, MPH5,6; Bryan McNally, MD, MPH4,7
doi : 10.1001/jamacardio.2020.6210
JAMA Cardiol. 2021;6(3):296-303
Importance Recent reports from communities severely affected by the coronavirus disease 2019 (COVID-19) pandemic found lower rates of sustained return of spontaneous circulation (ROSC) for out-of-hospital cardiac arrest (OHCA). Whether the pandemic has affected OHCA outcomes more broadly is unknown.
Objective Risk Assessment vs Standard Care for Acute Coronary Syndromes
Derek P. Chew, MBBS, MPH, PhD1; Karice Hyun, PhD2,3; Erin Morton, PhD1; Matt Horsfall, RN1; Graham S. Hillis, MBChB, PhD4; Clara K. Chow, MBBS, PhD2; Stephen Quinn, PhD5; Mario D’Souza, PhD2; Andrew T. Yan, MD6; Chris P. Gale, PhD7; Shaun G. Goodman, MD, MSc6; Keith Fox, MBChB8; David Brieger, MBBS, PhD9
doi : 10.1001/jamacardio.2020.6314
JAMA Cardiol. 2021;6(3):304-313
Importance Although international guidelines recommend use of the Global Registries of Acute Coronary Events (GRACE) risk score (GRS) to guide acute coronary syndrome (ACS) treatment decisions, the prospective utility of the GRS in improving care and outcomes is unproven.
Cardiac Structure and Function in Elite Female and Male Soccer Players
Timothy W. Churchill, MD1,2; Bradley J. Petek, MD1; Meagan M. Wasfy, MD1,2; James S. Guseh, MD1; Rory B. Weiner, MD1,2; Tamanna K. Singh, MD3; Christian Schmied, MD4; Hughie O’Malley, BA5; George Chiampas, MD5,6; Aaron L. Baggish, MD1,2,5
doi : 10.1001/jamacardio.2020.6088
JAMA Cardiol. 2021;6(3):316-325
Importance Population-specific normative data are essential for the evaluation of competitive athletes. At present, there are limited data defining normal electrocardiographic (ECG) and echocardiographic values among elite US soccer players.
Outcomes of Percutaneous Trans–Right Atrial Access to the Left Ventricle for Catheter Ablation of Ventricular Tachycardia in Patients With Mechanical Aortic and Mitral Valves
Pasquale Santangeli, MD, PhD1; Matthew C. Hyman, MD, PhD1; Daniele Muser, MD1; David J. Callans, MD1; Kalyanam Shivkumar, MD, PhD2; Francis E. Marchlinski, MD1
doi : 10.1001/jamacardio.2020.4414
JAMA Cardiol. 2021;6(3):326-331.
Importance In patients with mechanical valves in the aortic and mitral positions, percutaneous access to the left ventricle (LV) via a transfemoral approach for catheter ablation of ventricular tachycardia (VT) has been considered infeasible.
Misclassification of Hospital Performance Under the Hospital Readmissions Reduction Program
Changyu Shen, PhD1; Rishi K. Wadhera, MD, MPP, MPhil1; Robert W. Yeh, MD, MSc1
doi : 10.1001/jamacardio.2020.4746
JAMA Cardiol. 2021;6(3):332-335
Importance The Centers for Medicare and Medicaid Services (CMS) use point estimates of 30-day risk-standardized readmission rates (RSRRs) to compare hospitals under the Hospital Readmissions Reduction Program (HRRP). An important characteristic of this measure is that it is a point estimate with a margin of error, which may affect the CMS’s ability to accurately evaluate and distinguish hospital performance in the program.
Association of Early-Life Trauma and Risk of Adverse Cardiovascular Outcomes in Young and Middle-aged Individuals With a History of Myocardial Infarction
Zakaria Almuwaqqat, MD, MPH1,2; Matthew Wittbrodt, PhD3; An Young, MD, MPH1,2; Bruno B. Lima, MD, PhD1; Muhammad Hammadah, MD1; Mariana Garcia, MD1,2; Lisa Elon, MS, MPH4; Bradley Pearce, PhD2; Yingtian Hu, BS4; Samaah Sullivan, PhD2; Puja K. Mehta, MD1; Emily Driggers, MPH2; Ye Ji Kim, MPH2; Tene` T. Lewis, PhD2; Shakira F. Suglia, ScD, MS2; Amit J. Shah, MD, MSCR1,2,5; J. Douglas Bremner, MD3,5; Arshed A. Quyyumi, MD1; Viola Vaccarino, MD, PhD1,2
doi : 10.1001/jamacardio.2020.5749
JAMA Cardiol. 2021;6(3):336-340
Importance Compared with older patients, young adults with a history of myocardial infarction (MI) tend to have a higher burden of psychosocial adversity. Exposure to early-life stressors may contribute to the risk of adverse outcomes in this patient population, potentially through inflammatory pathways.
Genetic Inhibition of PCSK9 and Liver Function
Antoine Rimbert, PhD1; Sarra Smati, MD, PhD1; Wieneke Dijk, PhD1; Cédric Le May, PhD1; Bertrand Cariou, MD, PhD1
doi : 10.1001/jamacardio.2020.5341
JAMA Cardiol. 2021;6(3):353-354
no abstract
Trends in Hospitalizations for Heart Failure and Ischemic Heart Disease Among US Adults With Diabetes
Michael C. Honigberg, MD, MPP1; Ravi B. Patel, MD2; Ambarish Pandey, MD3; Gregg C. Fonarow, MD4,5; Javed Butler, MD, MPH, MBA6; Darren K. McGuire, MD, MHSc3; Muthiah Vaduganathan, MD, MPH7
doi : 10.1001/jamacardio.2020.5921
JAMA Cardiol. 2021;6(3):354-357
no abstract
Misfolded Transthyretin as a Novel Risk Factor for Heart Failure
Sanjiv J. Shah, MD1,2
doi : 10.1001/jamacardio.2020.5979
JAMA Cardiol. 2021;6(3):255-257
no abstract
Risk Stratification Science Goes to a New Level
Robert A. Harrington, MD1; E. Magnus Ohman, MBBS2
doi : 10.1001/jamacardio.2020.6325
JAMA Cardiol. 2021;6(3):314-315
no abstract
Mechanical Complications of Acute Myocardial Infarction
Fei Fei Gong, MBBS, PhD1; Inga Vaitenas, ACS1; S. Chris Malaisrie, MD2; Kameswari Maganti, MD1
doi : 10.1001/jamacardio.2020.3690
JAMA Cardiol. 2021;6(3):341-349
Importance Mechanical complications of acute myocardial infarction include left ventricular free-wall rupture, ventricular septal rupture, papillary muscle rupture, pseudoaneurysm, and true aneurysm. With the introduction of early reperfusion therapies, these complications now occur in fewer than 0.1% of patients following an acute myocardial infarction. However, mortality rates have not decreased in parallel, and mechanical complications remain an important determinant of outcomes after myocardial infarction. Early diagnosis and management are crucial to improving outcomes and require an understanding of the clinical findings that should raise suspicion of mechanical complications and the evolving surgical and percutaneous treatment options.
Urgent Need for Diagnosis of a Rapidly Growing Right Atrial Mass
Sneha Thatipelli, MD1; Sasan Raissi, MD2; Nausheen Akhter, MD3
doi : 10.1001/jamacardio.2020.6107
JAMA Cardiol. 2021;6(3):350-351
QT Interval in Patients With COVID-19
Matteo Bianco, MD1; Carlo Alberto Biolè, MD1; Enrico Cerrato, MD2,3
doi : 10.1001/jamacardio.2020.4952
JAMA Cardiol. 2021;6(3):357
QT Interval in Patients With COVID-19
Ingrid Berling, BMed, PhD1,2; Robert S. Hoffman, MD3; Sophie Gosselin, MD4
doi : 10.1001/jamacardio.2020.4955
JAMA Cardiol. 2021;6(3):357-358
QT Interval in Patients With COVID-19—Reply
Christina F. Yen, MD1; David J. Shim, MD, PhD2; Howard S. Gold, MD1
doi : 10.1001/jamacardio.2020.4958
JAMA Cardiol. 2021;6(3):358
Complications in Patients With COVID-19
Matthieu Legrand, MD, PhD1
doi : 10.1001/jamacardio.2020.5788
JAMA Cardiol. 2021;6(3):359
Complications in Patients With COVID-19
George A. Stavroulakis, MD, PhD1; George Koutroulis, MD, PhD1; Kourea Kallirrhoe, MD, PhD1
doi : 10.1001/jamacardio.2020.5791
JAMA Cardiol. 2021;6(3):359-360
Complications in Patients With COVID-19—Reply
Mohammad Madjid, MD, MS1; Scott D. Solomon, MD2; Orly Vardeny, PhD, MS3
doi : 10.1001/jamacardio.2020.5794
JAMA Cardiol. 2021;6(3):360
Exploring the Cardiac Phenotypes of Prematurity
Adam J. Lewandowski, DPhil1; Philip T. Levy, MD2
doi : 10.1001/jamacardio.2020.6056
JAMA Cardiol. 2021;6(3):361
Exploring the Cardiac Phenotypes of Prematurity—Reply
Kara N. Goss, MD1,2; Marlowe W. Eldridge, MD1,3,4
doi : 10.1001/jamacardio.2020.6059
JAMA Cardiol. 2021;6(3):361-362
Venoarterial Extracorporeal Membrane Oxygenation to Heart Transplant—An Inflamed Bridge?
Muddassir Mehmood, MD1
doi : 10.1001/jamacardio.2020.6115
JAMA Cardiol. 2021;6(3):362
Venoarterial Extracorporeal Membrane Oxygenation to Heart Transplant—An Inflamed Bridge?—Reply
Thomas C. Hanff, MD, MSCE1,2,3; Lee R. Goldberg, MD, MPH1,3; Edo Y. Birati, MD1,3
doi : 10.1001/jamacardio.2020.6127
JAMA Cardiol. 2021;6(3):362-363
Cost-effectiveness of Statin Use Guidelines
Conrad B. Blum, MD1; Neil J. Stone, MD2
doi : 10.1001/jamacardio.2020.6121
JAMA Cardiol. 2021;6(3):363-364
Cost-effectiveness of Statin Use Guidelines—Reply
Ankur Pandya, PhD1,2; Jinyi Zhu, MPH2; Aferdita Spahillari, MD, MPH3
doi : 10.1001/jamacardio.2020.6130
JAMA Cardiol. 2021;6(3):364.
